Segall Bryant & Hamill LLC Reduces Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Segall Bryant & Hamill LLC reduced its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 43,442 shares of the specialty pharmaceutical company’s stock after selling 1,430 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.21% of ANI Pharmaceuticals worth $2,401,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of ANIP. US Bancorp DE raised its holdings in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 531 shares during the last quarter. KBC Group NV increased its position in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after acquiring an additional 600 shares during the period. KLP Kapitalforvaltning AS purchased a new position in ANI Pharmaceuticals in the 4th quarter worth $166,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after acquiring an additional 579 shares during the period. Finally, HighTower Advisors LLC acquired a new position in shares of ANI Pharmaceuticals in the third quarter valued at about $222,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ANIP. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price for the company. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 14th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They set a “buy” rating and a $80.00 target price for the company. Finally, Guggenheim upped their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.75.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Meredith Cook sold 400 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,200 shares of company stock valued at $191,776. 12.70% of the stock is owned by company insiders.

ANI Pharmaceuticals Trading Up 1.8 %

ANIP stock opened at $68.36 on Friday. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.05. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.49 billion, a P/E ratio of -124.29 and a beta of 0.63. The company’s 50-day simple moving average is $60.31 and its 200-day simple moving average is $58.31.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.